This document describes the guidelines for antifungal susceptibility testing by the disk diffusion method of nondermatophyte filamentous fungi (moulds) that cause invasive disease.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Clinical and Laboratory Standards Institute

Setting the standard for quality in clinical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI’s consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Standards Development Policies and Process document.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: 610.688.0100
F: 610.688.0700
www.clsi.org
standard@clsi.org
Method for Antifungal Disk Diffusion Susceptibility Testing of Nondermatophyte Filamentous Fungi; Approved Guideline

Volume 30 Number 11

Ana Espinel-Ingroff, MS, PhD
Annette W. Fothergill, MA, MBA, MT(ASCP)
Mahmoud A. Ghannoum, MSc, PhD
Michael A. Pfaller, MD
John H. Rex, MD, FACP
Thomas J. Walsh, MD

Abstract

CLSI broth dilution reference methods are available for susceptibility testing of filamentous fungi (see CLSI document M38)\(^1\) and yeasts (see CLSI documents M27\(^2\) and M44\(^3\)). There still remains, however, a need for an alternative simple, rapid, and cost-effective approach to determine the susceptibility of nondermatophyte filamentous fungi (moulds) to various classes of antifungal agents that would make antifungal susceptibility testing more readily available to clinical microbiology laboratories. The CLSI Subcommittee on Antifungal Susceptibility Testing developed a disk diffusion method for testing filamentous fungi to amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole.\(^4\) Although clinical breakpoints have not been assigned, epidemiological cutoff values (ECVs) have been developed based on a comparison of zone diameters vs minimal inhibitory concentrations (MICs) or minimal effective concentrations (MECs) using the rate bounding method; control parameters for these agents have also been determined.\(^4\) ECVs are not used as clinical breakpoints, but rather to detect those isolates that are likely to have acquired resistance mechanisms or reduced susceptibility to the tested agent as compared with the wild-type distribution. One significant advantage of this method is that qualitative results can usually be determined after only 16 to 48 hours incubation as opposed to 24 to 72 hours with CLSI document M38.\(^1\) There are more antifungal agents and it is expected that this document will further encourage the development of disk diffusion testing for some of these agents.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.
Copyright ©2010 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation


Proposed Guideline
June 2009

Approved Guideline
May 2010

ISBN 1-56238-725-1
ISSN 0273-3099
Contents

Abstract.................................................................................................................................................i

Committee Membership........................................................................................................................ iii

Foreword.............................................................................................................................................. vii

1 Scope.............................................................................................................................................. 1

2 Standard Precautions.................................................................................................................. 1

3 Terminology.................................................................................................................................. 1

3.1 A Note on Terminology ................................................................................................ 1

3.2 Definitions ................................................................................................................... . 2

3.3 Abbreviations and Acronyms ....................................................................................... 3

4 Selection of Antimicrobial Agent Disks for Routine Testing and Reporting ....................... 3

4.1 Use of Nonproprietary or Generic Names .................................................................... 3

4.2 Number of Agents Tested ............................................................................................. 3

4.3 Suggested Guidelines for Selective Reporting.............................................................. 3

5 Equipment/Materials.................................................................................................................. 4

6 Test Procedures.......................................................................................................................... 4

6.1 Nonsupplemented Mueller-Hinton Agar Medium (see Appendix B)........................... 4

7 Procedure for Performing the Disk Diffusion Test.......................................................... 5

7.1 Inoculum Preparation.................................................................................................... 5

7.2 Inoculum Quantitation .................................................................................................. 6

7.3 Inoculation of Test Plates.............................................................................................. 6

7.4 Application of Disks to Inoculated Agar Plates ............................................................ 7

7.5 Reading Plates and Interpreting Results ....................................................................... 7

8 Interpretation of Disks Diffusion Test Results ........................................................................ 7

8.1 Zone Diameter Epidemiological Cutoff Values ............................................................ 7

9 Quality Control Procedures........................................................................................................ 8

9.1 Purpose ............................................................................................................................... 8

9.2 Standard Reference Strains for Control ........................................................................ 8

9.3 Storing Reference Strains .............................................................................................. 8

9.4 Zone Diameter Reference Control Limits ..................................................................... 9

9.5 Frequency of Control Testing .......................................................................................... 9

9.6 Corrective Action................................................................................................................ 10

9.7 Reporting Patient Results When Out-of-Range Results Occur................................. 11

10 Limitations of Disk Diffusion Method................................................................................... 11

10.1 Application to Various Organism Groups ................................................................. 11

10.2 Verification of Patient Results ...................................................................................... 12

References........................................................................................................................................... 13

Appendix A. Performance of Nonsupplemented Mueller-Hinton Agar .................................. 15
Appendix B. Preparation of Nonsupplemented Mueller-Hinton Agar ....................................................... 16

Appendix C. McFarland 0.5 Barium Sulfate Turbidity Standard ............................................................... 17

Appendix D. Quality Control Protocol Flow Charts ................................................................................ 18

Summary of Delegate Comments and Subcommittee Responses .......................................................... 20

The Quality Management System Approach ......................................................................................... 28

Related CLSI Reference Materials ........................................................................................................ 29


Foreword

Due to the increased incidence of systemic fungal infections and the number of antifungal agents, antifungal susceptibility testing has gained greater recognition. Broth dilution reference methods are now available for susceptibility testing of filamentous fungi (moulds) (see CLSI document M38). There still remains a need for alternative, simple, rapid, and cost-effective approaches to determine the antifungal susceptibility of these fungi. Disk diffusion methodology has served as an example for yeast testing. A collaborative study has identified parameters for testing the susceptibilities of filamentous fungi to five antifungal agents (amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole) by the disk diffusion method. This method often provides qualitative results 8 to 24 hours sooner than the standard CLSI document M38 method. In addition, the use of nonsupplemented Mueller-Hinton agar in lieu of supplemented Mueller-Hinton agar should make antifungal susceptibility testing more readily available to clinical laboratories at a reduced cost. Although clinical breakpoints have not been assigned, tentative epidemiological cutoff values (ECVs) have been developed, based on a comparison of zone diameters vs minimal inhibitory concentrations (MICs) or minimal effective concentrations (MECs) using the rate bounding method. The ECVs are used to detect those isolates with reduced susceptibility to the tested agent as compared with the wild-type distribution. ECVs are not used as clinical breakpoints, but rather to detect those isolates that are likely to have acquired resistance mechanisms.

Key Words

Antifungal, antimicrobial, disk, disk diffusion, Kirby-Bauer method, susceptibility testing
Method for Antifungal Disk Diffusion Susceptibility Testing of Nondermatophyte Filamentous Fungi; Approved Guideline

1 Scope

With a need to make antifungal susceptibility testing more readily available to the clinical laboratory, this CLSI document provides an established method for disk diffusion testing of moulds, zone interpretive criteria, and recommended control ranges for amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole.

The method described in this document is intended for testing moulds that cause invasive disease (*Alternaria* spp., *Aspergillus* spp., *Bipolaris* spp., *Fusarium* spp., *Paecilomyces* spp., *Rhizopus* *oryzae* [*R. arrhizus*] and other mucoraceous [zygomycetes] mould species, the *Pseudallescheria boydii* species complex, and *Scedosporium prolificans*). This method does not currently encompass the yeast or mould form of endemic dimorphic fungi or the dermatophytes.

The method described herein must be followed exactly to obtain reproducible results. When new problems are recognized or improvements in these criteria are developed, changes will be incorporated into future editions of this guideline and also distributed in periodic informational supplements.

This guideline is intended for use by, but not limited to, health care, academic, government, industry, or independent research organizations that perform antifungal susceptibility testing of filamentous fungi.

2 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the US Centers for Disease Control and Prevention. For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29.

3 Terminology

3.1 A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in CLSI, International Organization for Standardization (ISO), and European Committee for Standardization (CEN) documents; and that legally required use of terms, regional usage, and different consensus timelines are all important considerations in the harmonization process. In light of this, CLSI’s consensus process for development and revision of standards and guidelines focuses on harmonization of terms to facilitate the global application of standards and guidelines.

Of particular note in CLSI document M51-A are two terms whereby CLSI intends to eliminate confusion over time through its commitment to harmonization. For the most part, in this guideline, the term
“accuracy,” in its metrological sense, refers to the closeness of the agreement between the result of a single measurement and a true value of a measurand, thus comprising both random and systematic effects. The term “trueness,” usually used to replace the term “accuracy” when referring to the closeness of agreement does not apply in M51-A because it refers to the closeness of agreement between the average value obtained from a large series of test results and an accepted reference value.

3.2 Definitions

accuracy (measurement) – closeness of agreement between a measured quantity value and a true quantity value of a measurand (ISO/IEC Guide 99).14

clinical breakpoint – 1) a classification based on an in vitro response of an organism to an antimicrobial agent at levels corresponding to blood or tissue levels attainable with usually prescribed doses; 2) susceptible clinical breakpoint – a category that implies that an infection due to the isolate may be appropriately treated with the dosage of an antimicrobial agent recommended for that type of infection and infecting species, unless otherwise contraindicated; 3) intermediate clinical breakpoint – a category that includes isolates with antimicrobial agent minimal inhibitory concentrations (MICs) or minimal effective concentrations (MECs) that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates; 4) resistant clinical breakpoint – a category that includes resistant isolates that are not inhibited by the usually achievable concentrations of the agent with normal dosage schedules or where clinical efficacy has not been reliable in treatment studies.

epidemiological cutoff value (ECV) – the ECV for each agent is the value obtained by considering the wild-type distribution, the modal MIC/MEC for each distribution, and the inherent variability of the test. Usually, the ECV encompasses at least 95% of isolates in the wild-type distribution15; NOTE: Organisms with acquired resistance mechanisms may be included among those for which the MICs/MECs are higher than the ECV (for disk testing, those with acquired resistance mechanisms would show a zone diameter smaller than the ECV).

minimal effective concentration (MEC) – the lowest concentration of an antimicrobial agent that leads to the growth of small, rounded, compact hyphal forms as compared to the hyphal growth seen in the growth control well; NOTE: This terminology is currently used only with respect to testing of the echinocandin antifungal agents.

minimal inhibitory concentration (MIC) – the lowest concentration of an antimicrobial agent that causes a specified reduction in visible growth of a microorganism in an agar or broth dilution susceptibility test.

modal MIC/MEC – the most frequent MIC or MEC found within an MIC or MEC distribution.

precision (measurement) – closeness of agreement between indications or measured quantity values obtained by replicate measurements on the same or similar objects under specified conditions (ISO/IEC Guide 99).14

quality control – part of quality management focused on fulfilling quality requirements (ISO 9000)16; NOTE: This includes operational techniques and activities used to fulfill these requirements.

reproducibility (measurement) – measurement precision (closeness of agreement between indications or measured quantity values obtained by replicate measurements on the same or similar objects under specified conditions) under reproducibility conditions of measurement (condition of measurement, out of a set of conditions that includes different locations, operators, measuring systems, and replicate measurements on the same or similar objects) (ISO/IEC Guide 99).14
The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents. The approach is based on the model presented in CLSI document HS01—A Quality Management System Model for Health Care. The quality management system approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are as follows:

Documents and Records
Organization
Personnel
Equipment
Purchasing and Inventory
Information Management
Occurrence Management
Process Improvement
Assessments—External and Internal
Facilities and Safety

M51-A addresses the QSEs indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

Path of Workflow

A path of workflow is the description of the necessary steps to deliver the particular product or service that the organization or entity provides. For example, CLSI document GP26—Application of a Quality Management System Model for Laboratory Services defines a clinical laboratory path of workflow, which consists of three sequential processes: preexamination, examination, and postexamination. All clinical laboratories follow these processes to deliver the laboratory’s services, namely quality laboratory information.

M51-A addresses the clinical laboratory path of workflow steps indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.
Related CLSI Reference Materials*

I/LA21-A2 Clinical Evaluation of Immunoassays; Approved Guideline—Second Edition (2008). This document addresses the need for clinical evaluation of new immunoassays and new applications of existing assays, as well as multiple assay formats and their uses. As a guide to designing and executing a clinical evaluation, this document will aid developers of “in-house” assays for institutional use, developers of assays used for monitoring pharmacologic effects of new drugs or biologics, and clinical and regulatory personnel responsible for commercializing products.


M23-A3 Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters; Approved Guideline—Third Edition (2008). This document addresses the required and recommended data needed for the selection of appropriate interpretive criteria and quality control ranges for antimicrobial agents.


M29-A3 Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline—Third Edition (2005). Based on US regulations, this document provides guidance on the risk of transmission of infectious agents by aerosols, droplets, blood, and body substances in a laboratory setting; specific precautions for preventing the laboratory transmission of microbial infection from laboratory instruments and materials; and recommendations for the management of exposure to infectious agents.


M51-S1 Performance Standards for Antifungal Disk Diffusion Susceptibility Testing of Nondermatophyte Filamentous Fungi; Informational Supplement (2010). These supplemental tables provide zone diameter reference limits for CLSI document M51-A.

* CLSI documents are continually reviewed and revised through the CLSI consensus process; therefore, readers should refer to the most current editions.
Explore the Latest Offerings from CLSI!

As we continue to set the global standard for quality in laboratory testing, we’re adding initiatives to bring even more value to our members and customers.

Visit the CLSI U Education Center
Where we provide the convenient and cost-effective education resources that laboratories need to put CLSI standards into practice, including webinars, workshops, and more.

Shop Our Online Products
Including eM100, the interactive searchable database for drug selection, interpretation, and quality control procedures within M100-S23.

Find Membership Opportunities
See the options that make it even easier for your organization to take full advantage of CLSI benefits and our unique membership value.

For more information, visit www.clsi.org today.